C4 Therapeutics, Inc. (CCCC) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CCCC Revenue Growth
CCCC Revenue Analysis (2018–2025)
As of May 8, 2026, C4 Therapeutics, Inc. (CCCC) generated trailing twelve-month (TTM) revenue of $35.9 million, reflecting explosive growth of +112.8% year-over-year. The most recent quarter (Q4 2025) recorded $11.0 million in revenue, down 1.9% sequentially.
Looking at the longer-term picture, CCCC's 5-year compound annual growth rate (CAGR) stands at +1.6%, indicating moderate growth over time. The company achieved its highest annual revenue of $45.8 million in 2021.
When compared to Healthcare sector peers including ARVN (-0.3% YoY), KYMR (-12.6% YoY), and VRTX (+10.4% YoY), CCCC has outperformed the peer group in terms of revenue growth. Compare CCCC vs ARVN →
CCCC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CCCCCurrent | $36M | +112.8% | +1.6% | -290.7% | |
 ARVN | $263M | -0.3% | +58.9% | -43.8% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 VRTX | $12.1B | +10.4% | +14.2% | 39.4% | |
 AUPH | $283M | +20.4% | +41.4% | 37.1% |
CCCC Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $35.9M | +1.0% | $28.0M | 77.8% | $-104,489,000 | -290.7% |
| 2024 | $35.6M | +71.4% | $35.6M | 100.0% | $-119,614,000 | -336.1% |
| 2023 | $20.8M | -33.3% | $13.0M | 62.7% | $-139,031,000 | -669.8% |
| 2022 | $31.1M | -32.1% | $31.1M | 100.0% | $-129,534,000 | -416.6% |
| 2021 | $45.8M | +37.9% | $45.8M | 100.0% | $-82,134,000 | -179.4% |
| 2020 | $33.2M | +55.3% | $-45,245,000 | -136.3% | $-60,449,000 | -182.1% |
| 2019 | $21.4M | +10.4% | $21.4M | 100.0% | $-35,452,000 | -165.8% |
| 2018 | $19.4M | - | $-9,228,000 | -47.7% | $-16,389,000 | -84.6% |
See CCCC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CCCC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CCCC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCCCC — Frequently Asked Questions
Quick answers to the most common questions about buying CCCC stock.
Is CCCC's revenue growth accelerating or slowing?
CCCC revenue is accelerating at +112.8% year-over-year, exceeding the 5-year CAGR of +1.6%. TTM revenue reached $36M. Growth momentum has increased versus prior periods.
What is CCCC's long-term revenue growth rate?
C4 Therapeutics, Inc.'s 5-year revenue CAGR of +1.6% reflects the sustained expansion pattern. Current YoY growth of +112.8% is above this long-term average.
How is CCCC's revenue distributed by segment?
CCCC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.